SGLT

Global Chronic Kidney Disease (CKD) Pipeline Landscape Report 2022: Comprehensive Insights About 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Other Health, Gynecomastia, Chronic kidney disease, Risk, Gout, CKD, Waste, Metabolic disorder, Blood, II, Hypertension, Blood pressure, News, Patient, Hirsutism, Moderate, Mergers and acquisitions, Obesity, Probiotic, MRA, Clinical trial, Arthritis, Progesterone, Nutrient, III, Technology, LAP, Empagliflozin, Aldosterone, NDA, TGF, Boehringer Ingelheim, Therapy, Kidney, SGLT, Discovery, Acquisition, KBP, Pharmaceutical industry, Poultry, Hyperuricemia

This "Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic-kidney-disease-chronic-renal-failure pipeline landscape.

Key Points: 
  • This "Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic-kidney-disease-chronic-renal-failure pipeline landscape.
  • A detailed picture of the Chronic-kidney-disease-chronic-renal-failure pipeline landscape is provided which includes the disease overview and Chronic-kidney-disease-chronic-renal-failure treatment guidelines.
  • The assessment part of the report embraces, in depth Chronic-kidney-disease-chronic-renal-failure commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic-kidney-disease-chronic-renal-failure R&D.

Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical Update

Retrieved on: 
Wednesday, November 3, 2021
The New England Journal of Medicine, Heart failure with preserved ejection fraction, Gene, Disease, SGLT2, Annual report, Fortis Healthcare, SGLT, Neuropathic pain, European Society of Cardiology, Diabetes, Myocardial infarction, Type 2 diabetes, History, Security (finance), U.S. Securities and Exchange Commission, Adoption, SGLT1, SG, Cardiovascular disease, American Heart Association, EGFR, Investment, Trigeminal neuralgia, ID, Doctor of Philosophy, Chronic kidney disease, Income, AHA, Marketing, Protein, Research and development, Webcast, Stroke, Holocene, NEJM, Form 10-K, Metabolism, Nasdaq, Research, Therapy, Death, R, Intellectual property, Risk, GLOBE, Administration, Sale, General officer, Heart failure, ESC, Cryptocurrency, Pharmaceutical industry, Air cargo

THE WOODLANDS, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones.

Key Points: 
  • THE WOODLANDS, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones.
  • Results from these clinical studies are currently expected in the first half of 2022.
  • Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.
  • Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care

Retrieved on: 
Monday, August 30, 2021
Union, HF, Fortis Healthcare, Diabetes, European Society of Cardiology, Annual report, Quality of life, Body mass index, U.S. Securities and Exchange Commission, Gene, Protein, GLOBE, SGLT1, Hospital, European Union, Neuropathic pain, Canagliflozin, Nasdaq, Food, Disease, Kidney, Death, SGLT, Metabolism, Intellectual property, SGLT2, Roy Taylor (scientist), T2DM, Risk, Review, CV, Lexicon Pharmaceuticals, Trust, Gastrointestinal tract, Form 10-K, ESC, Patient, LVEF, The X Factor Digital Experience, Heart failure, Security (finance), ESC Congress, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Medical device

THE WOODLANDS, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes the new recommendation by the European Society of Cardiology (ESC) to add SGLT inhibitors as part of the standard of care for the prevention and treatment of heart failure (HF). SGLT inhibitors have been given a Class IA recommendation-- the strongest endorsement-- in updated clinical practice guidelines released by the ESC Heart Failure working group in the EU at its annual meeting, the ESC Congress 2021 - The Digital Experience.

Key Points: 
  • New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure.
  • Guidance underscores the benefits of SGLT inhibitors in significantly reducing risk of death due to cardiovascular causes or heart failure hospitalization.
  • THE WOODLANDS, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes the new recommendation by the European Society of Cardiology (ESC) to add SGLT inhibitors as part of the standard of care for the prevention and treatment of heart failure (HF).
  • SGLT inhibitors have been given a Class IA recommendation-- the strongest endorsement-- in updated clinical practice guidelines released by the ESC Heart Failure working group in the EU at its annual meeting, the ESC Congress 2021 - The Digital Experience.